Galvus is a brand of tablets containing the active ingredient vildagliptin. It is only available with a doctor’s prescription.
Galvus belongs to a group of diabetes medicines called DPP-4 inhibitors, or dipeptidyl peptidase-4 inhibitors. Galvus is used to lower blood sugar levels in people with type 2 diabetes mellitus.
Galvus is taken along with certain other diabetes medicines if you are unable to take a diabetes medicine called metformin. It is used to control your blood sugar level. You should continue to follow your healthcare professional’s recommendations on diet and physical activity to manage your diabetes.
Galvus tablets are to be swallowed whole with a glass of water.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
Active ingredient in this medicine: vildagliptin
Information for medicine and pack size:
Galvus 50 mg uncoated tablet, 60
Consumer Medicine Information leaflet:
This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.
What this medicine is for
Treatment of diabetes mellitus type 2 in persons 18 years of age and older, as an adjunct to diet and exercise to improve glycaemic control in patients with type 2 diabetes:
- As monotherapy, in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance.
- In dual combination with one of metformin, a sulfonylurea or pioglitazone when diet, exercise and the single agent do not result in adequate glycaemic control.
- In triple combination with a sulfonylurea and metformin when diet and exercise plus dual therapy with these agents do not provide adequate glycaemic control.
- In combination with insulin (with or without metformin) when diet, exercise and a stable
dose of insulin do not result in adequate glycaemic control.
Table of characteristics
Table of characteristics
White to light yellowish, round, flat faced, bevelled edge tablet. One side debossed with 'NVR' and the other side with 'FB'.
Images are the copyright of the Pharmacy Guild of Australia
|Route of administration
112 tablets: Prescription Only Medicine, or Prescription Animal Remedy
14 tablets: Prescription Only Medicine, or Prescription Animal Remedy
28 tablets: Prescription Only Medicine, or Prescription Animal Remedy
56 tablets: Prescription Only Medicine, or Prescription Animal Remedy
7 tablets: Prescription Only Medicine, or Prescription Animal Remedy
There is one type of pack available.
Pack type 1
Pack type 1
||Store below 30 degrees Celsius
||Protect from Moisture
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on 1 November 2017
The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.
Go to PBS site
Is this medication banned in sport?
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.
Go to ASADA site